The DEP® irinotecan data will be presented at the ASCO Meeting by Dr Jia (Jenny) Liu MD PhD FRACP, Medical Oncologist and Principal Investigator at the Kinghorn Cancer Centre, St Vincent’s Hospital in Sydney, who commented on the positive Phase 1/2 clinical trial results:
“The full DEP® irinotecan / DEP® SN38 trial results are very exciting. DEP® irinotecan in heavily pre-treated, advanced cancer patients demonstrated highly encouraging efficacy results in a range of tumour types. These responses include significant and sustained tumour shrinkage and disease control in patients with irinotecan-pre-treated colorectal cancer and platinum-resistant ovarian cancer.
“Furthermore, DEP® irinotecan exhibits excellent tolerability, with a distinct lack of severe gastrointestinal toxicity that is a common and problematic feature of standard irinotecan treatment. Such treatment tolerability, combined with sustained disease control, has meant that many of our patients, including those who are quite young with advanced colorectal cancer, have been able to receive long-term treatment and continue to work and engage socially with their peers, which is very important for their quality of life.
“I’m impressed by the DEP® delivery platform, which is highly flexible and has the potential to more effectively deliver a broad range of compounds, including other cytotoxic and small molecules, as well as radioisotopes, and as a potential alternative to antibody-drug conjugates (ADCs) to treat and image cancers, while avoiding or reducing possible adverse effects.
“The ASCO annual meeting is the world’s biggest global clinical cancer conference. It’s noteworthy that these exciting DEP® irinotecan trial results were chosen for an oral presentation, and we are delighted to showcase this very promising and flexible DEP® delivery platform to this important audience.”
- Forums
- ASX - By Stock
- SPL
- Ann: Positive final DEP irinotecan Phase 2 clinical trial results
Ann: Positive final DEP irinotecan Phase 2 clinical trial results, page-26
-
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.008(9.20%) |
Mkt cap ! $39.14M |
Open | High | Low | Value | Volume |
9.0¢ | 9.5¢ | 8.8¢ | $334.2K | 3.710M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 50354 | 9.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.5¢ | 22908 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 760087 | 0.089 |
2 | 147200 | 0.087 |
3 | 118061 | 0.086 |
3 | 220000 | 0.085 |
1 | 100000 | 0.084 |
Price($) | Vol. | No. |
---|---|---|
0.095 | 22908 | 2 |
0.096 | 5000 | 1 |
0.099 | 6837 | 1 |
0.100 | 71848 | 3 |
0.105 | 370000 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online